Skip to content

Neurogene

US · NGNE #3726 by market cap
22.15 -0.78 -3.40%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 22.97 +0.19%
After-hours 22.15 0.00%
42.8421.5622.152026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NGNE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -16.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 28.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -8,930.3% Better than 1%
Net margin -8,123.7% Better than 1%
Return on equity -31.4% Better than 12%
Return on invested capital -33.9% Better than 9%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -42.7% Better than 9%
6-month return -20.1% Better than 27%
12-month return (ex latest month) 17.4% Better than 56%
Distance below 52-week high 49.3% Better than 19%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 16.6x Better than 97%
Debt to assets 3.8% Better than 82%
Interest coverage -18,069.2x Better than 0%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 309.3% Better than 98%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.44%
1M -12.80%
3M -41.70%
6M -17.81%
YTD +7.52%
1Y +8.58%
3Y +67.80%
5Y -79.10%

Key statistics

Price & volume

Prev close
22.93
Open
22.27
Day range
22.03 - 22.90
Avg price
22.31
Volume
178.27K
Turnover
3.98M
Amplitude
3.79%
52-week range
15.93 - 43.66

Valuation

P/E
-5.22
P/E (TTM)
-4.40
P/B
1.29
EPS
-4.24
Net profit
-87.77M
Net assets
354.79M

Share structure

Market cap
458.53M
Float cap
296.07M
Shares out
20.70M
Float shares
13.37M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 22% of range
15.93 43.66

49.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-134.67K net over the window

Short interest

Shares short
5.69M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Neurogene (NGNE)?

Neurogene last traded at 22.15. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Neurogene's market cap?

About 458.53M.

What is the P/E ratio of Neurogene?

The trailing twelve-month P/E is -4.40. The Valuation tab shows it against the stock's own five-year range.

Does Neurogene pay a dividend?

Neurogene does not currently pay a regular dividend.

Is Neurogene a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 90.67, which implies 309.3% upside from the current price. This is not investment advice.

What is Neurogene's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Neurogene a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Neurogene discussion 0 comments

Add a comment